Anixa Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>AB</div>
ANIX -- USA Stock  

USD 4.43  0.24  5.73%

Given the investment horizon of 60 days Anixa Biosciences is expected to generate 4.87 times more return on investment than the market. However, the company is 4.87 times more volatile than its market benchmark. It trades about 0.12 of its potential returns per unit of risk. The DOW is currently generating roughly 0.07 per unit of risk. While some risk-seeking investors are getting worried about healthcare space, it is reasonable to break down Anixa Biosciences as a possible investment alternative. We are going to inspect if the current expected returns justify Anixa Biosciences' volatility.
Published over a month ago
View all stories for Anixa Biosciences | View All Stories
Is Anixa Biosciences (NASDAQ:ANIX) rise viable based on current volatility?
Anixa Biosciences currently holds about 9.07 M in cash with (6.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. On a scale of 0 to 100, Anixa Biosciences holds a performance score of 8. The firm shows a Beta (market volatility) of 1.0503, which signifies a somewhat significant risk relative to the market. Let's try to break down what Anixa's beta means in this case. Anixa Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Anixa Biosciences is expected to follow. Although it is vital to follow Anixa Biosciences historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-one technical indicators for Anixa Biosciences, which you can use to evaluate the performance of the firm. Please makes use of Anixa Biosciences semi deviation, jensen alpha, as well as the relationship between the Jensen Alpha and semi variance to make a quick decision on whether Anixa Biosciences price patterns will revert.
Volatility is a rate at which the price of Anixa Biosciences or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Anixa Biosciences may increase or decrease. In other words, similar to Anixa's beta indicator, it measures the risk of Anixa Biosciences and helps estimate the fluctuations that may happen in a short period of time. So if prices of Anixa Biosciences fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our technical analysis page.

How important is Anixa Biosciences's Liquidity

Anixa Biosciences financial leverage refers to using borrowed capital as a funding source to finance Anixa Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Anixa Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Anixa Biosciences's total debt and its cash.

How Anixa utilizes its cash?

To perform a cash flow analysis of Anixa Biosciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Anixa Biosciences is receiving and how much cash it distributes out in a given period. The Anixa Biosciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Anixa Biosciences Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Anixa Biosciences reported Net Cash Flow from Operations of (5.56 Million) in 2020

Anixa Biosciences Volatility Drivers

Anixa Biosciences unsystematic risk is unique to Anixa Biosciences and usually not directly affected by the market or economic environment. An example of unsystematic risk is the possibility of poor earnings or a layoff due to coronavirus. One may mitigate nonsystematic risk by buying different securities in the same industry or by buying in different sectors. For example, if you have a position in Anixa Biosciences you can also buy DarioHealth Corp. You can also mitigate this risk by investing in the diagnostics & research sector as well as in companies having nothing to do with it. This type of risk is also called diversifiable risk and can be understood from analyzing Anixa Biosciences important indicators over time. Here we run a correlation analysis between relevant fundamental ratios over at least ten year period to find a relationship in the way they react to changes in Anixa Biosciences income statement and balance sheet. Here are more details about Anixa volatility.